Authorized purpose: Create, review, analyze, annotate, export, and use 3D cardiac models to support reading, reporting, and therapeutic-intervention planning.
Clinical role
AI-assisted initial 3D segmentation/modeling followed by review, editing, visualization, reporting, and treatment-planning support.
Images and patients
CT/CTA; MRI · Cardiac structures, including the aorta, atria, ventricles, pulmonary artery trunk, and right atrium/inferior vena cava structures described in the FDA performance table
Key limitation
Keep in mind: The AI module is adult and CT-only. The product is not intended for use with or primary diagnostic interpretation of mammography images. The FDA performance criteria expressly describe the AI module as an initialization step that does not replace manual expert segmentation; users review and edit outputs in the cleared suite.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Create, review, analyze, annotate, export, and use 3D cardiac models to support reading, reporting, and therapeutic-intervention planning.
Which images or clinical context are in scope?Modality: CT/CTA; MRI Anatomy or clinical context: Cardiac structures, including the aorta, atria, ventricles, pulmonary artery trunk, and right atrium/inferior vena cava structures described in the FDA performance table Input: DICOM-compliant pre-operative CT and MR images for the suite; inHEART Models AI specifically preprocesses CT images and is indicated for adults only.
Who uses it?Intended users: Qualified medical professionals, including physicians, cardiologists, radiologists, and technicians; final patient-management decisions remain with the users.
What does the software produce?Output: Automatic initial 3D segmentation/modeling from the AI module, followed by 3D cardiac models that can be displayed, reviewed, analyzed, annotated, exported, reported, and used for therapeutic planning. The packet describes 2D/3D viewers, quantitative analysis, and manual/semi-automated review and editing.
What is its most important limitation?Key limitation: The AI module is adult and CT-only. The product is not intended for use with or primary diagnostic interpretation of mammography images. The FDA performance criteria expressly describe the AI module as an initialization step that does not replace manual expert segmentation; users review and edit outputs in the cleared suite.
Clinical takeaway. Clinical role: Create, review, analyze, annotate, export, and use 3D cardiac models to support reading, reporting, and therapeutic-intervention planning.
Evidence takeaway. Evidence from the reviewed source record: FDA packet: 100 independent CT cases selected from 2023; two external experts established the ground truth. Performance was calculated on revised expert segmentations based on AI initialization versus ground truth/predicate outputs, rather than on unreviewed AI output alone. Average Dice was 0.94, average ASSD 1.17 mm, and average volume variation 9.18 mL/7%.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Create, review, analyze, annotate, export, and use 3D cardiac models to support reading, reporting, and therapeutic-intervention planning.
Automatic initial 3D segmentation/modeling from the AI module, followed by 3D cardiac models that can be displayed, reviewed, analyzed, annotated, exported, reported, and used for therapeutic planning. The packet describes 2D/3D viewers, quantitative analysis, and manual/semi-automated review and editing.
Qualified medical professionals, including physicians, cardiologists, radiologists, and technicians; final patient-management decisions remain with the users.
The AI module is adult and CT-only. The product is not intended for use with or primary diagnostic interpretation of mammography images. The FDA performance criteria expressly describe the AI module as an initialization step that does not replace manual expert segmentation; users review and edit outputs in the cleared suite.
FDA packet: 100 independent CT cases selected from 2023; two external experts established the ground truth. Performance was calculated on revised expert segmentations based on AI initialization versus ground truth/predicate outputs, rather than on unreviewed AI output alone. Average Dice was 0.94, average ASSD 1.17 mm, and average volume variation 9.18 mL/7%.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA packet: 100 independent CT cases selected from 2023; two external experts established the ground truth. Performance was calculated on revised expert segmentations based on AI initialization versus ground truth/predicate outputs, rather than on unreviewed AI output alone. Average Dice was 0.94, average ASSD 1.17 mm, and average volume variation 9.18 mL/7%.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
inHEART Models regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K231683
Samplen=100
IndependenceIndependence not established
K231683
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231683. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM-compliant pre-operative CT and MR images for the suite; inHEART Models AI specifically preprocesses CT images and is indicated for adults only.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Standalone and web-based software suite. The packet specifies DICOM-compliant input, a macOS imaging-processing module, a Windows/macOS web platform with supported browsers, and a standard internet connection for the web platform; exact local interface versions and deployment topology are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes a standalone and web-based software suite, including inHEART MODELS Explorer, a web-based 3D visualization software, with a standard internet connection needed for the web-based platform. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "inHEART MODELS Explorer: a web-based 3D visualization software that permits display, review, analysis, annotation and export of the cardiac 3D models" … "Mode of operation Standalone and web-based Standalone and web-based software suite software suite". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Automatic initial 3D segmentation/modeling from the AI module, followed by 3D cardiac models that can be displayed, reviewed, analyzed, annotated, exported, reported, and used for therapeutic planning. The packet describes 2D/3D viewers, quantitative analysis, and manual/semi-automated review and editing.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Automatic initial 3D segmentation/modeling from the AI module, followed by 3D cardiac models that can be displayed, reviewed, analyzed, annotated, exported, reported, and used for therapeutic planning. The packet describes 2D/3D viewers, quantitative analysis, and manual/semi-automated review and editing.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes a standalone and web-based software suite, including inHEART MODELS Explorer, a web-based 3D visualization software, with a standard internet connection needed for the web-based platform. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "inHEART MODELS Explorer: a web-based 3D visualization software that permits display, review, analysis, annotation and export of the cardiac 3D models" … "Mode of operation Standalone and web-based Standalone and web-based software suite software suite". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Standalone and web-based software suite. The packet specifies DICOM-compliant input, a macOS imaging-processing module, a Windows/macOS web platform with supported browsers, and a standard internet connection for the web platform; exact local interface versions and deployment topology are not established.
inHEART's regulatory page lists SOC 2 Type 2 and HIPAA Compliance alongside its ISO 13485 and CE certificates.
Vendor-wide
Checked 2026-10-27
Vendor statements, not attestations. No SOC 2 report or HIPAA assessment was read; the page names inHEART generally and does not scope the claims to inHEART Models or any specific release; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for inHEART Models; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Cardiac structures, including the aorta, atria, ventricles, pulmonary artery trunk, and right atrium/inferior vena cava structures described in the FDA performance table
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
9Source classes checked
2Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K231683 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: View, post-process, and qualitatively and quantitatively evaluate cardiovascular MR and CT images in DICOM format to obtain diagnostic information as part of a comprehensive diagnostic decision-making process.
Modality
CT/CTA; MRI
Anatomy
Cardiovascular system; heart, coronary and adjacent vessels, and cardiac valves
Authorized purpose: Support-tool image processing for quantitative cardiovascular assessment and oncologic lesion evaluation, quantification, follow-up, and documentation to aid trained healthcare professionals in diagnosis; the software does not directly generate a diagnosis or potential findings.
Modality
CT/CTA; MRI
Anatomy
Heart and major vessels for Cardio AI; oncology lesion anatomy is not further specified in the FDA statement.
Authorized purpose: DICOM/non-DICOM image and data management with optional quantitative cardiac MR and oncology lesion evaluation, quantification, follow-up, and documentation support; the software does not directly generate a diagnosis or potential findings.
Modality
CT/CTA; MRI
Anatomy
Heart and major vessels for the optional Cardio AI module; lung and liver lesions or nodules for the optional Oncology AI module; the base viewer handles broader radiological image data.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.